Grifols (GIFLF) Net Income towards Common Stockholders Growth (1y) (2011 - 2020)
Grifols (GIFLF) Net Income towards Common Stockholders Growth (1y) (2011 - 2020) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Net Income Growth (1y) (Qtr) |
| 1 |
Gsk |
96,436,181.12 Bn |
96,436,176.16 Bn |
7.76 Bn |
14.49% |
| 2 |
Eli Lilly |
1,017.30 Bn |
1,012.01 Bn |
16.22 Bn |
168.07% |
| 3 |
Johnson & Johnson |
579.61 Bn |
557.55 Bn |
15.96 Bn |
-52.40% |
| 4 |
AbbVie |
402.30 Bn |
392.96 Bn |
10.78 Bn |
-45.93% |
| 5 |
Merck |
294.24 Bn |
288.59 Bn |
12.09 Bn |
-182.77% |
| 6 |
Amgen |
191.82 Bn |
179.78 Bn |
5.87 Bn |
5.14% |
| 7 |
Gilead Sciences |
155.93 Bn |
148.21 Bn |
5.52 Bn |
53.69% |
| 8 |
Pfizer |
149.05 Bn |
136.28 Bn |
-1.21 Bn |
- |
| 9 |
Bristol Myers Squibb |
116.33 Bn |
105.88 Bn |
8.07 Bn |
8.81% |
| 10 |
Grifols |
- |
- |
- |
- |
| Date | Value |
|---|
| Mar 31, 2020 |
69.41% |
| Dec 31, 2019 |
-7.63% |
| Mar 31, 2019 |
-26.23% |
| Dec 31, 2018 |
-9.06% |
| Jun 30, 2018 |
-17.86% |
| Mar 31, 2018 |
6.56% |
| Dec 31, 2017 |
486.37% |
| Jun 30, 2017 |
25.77% |
| Mar 31, 2017 |
-24.24% |
| Dec 31, 2016 |
5.16% |
| Sep 30, 2016 |
190.87% |
| Jun 30, 2016 |
137,874.31% |
| Mar 31, 2016 |
125.39% |
| Sep 30, 2013 |
39.79% |
| Jun 30, 2013 |
41.41% |
| Mar 31, 2013 |
35.69% |
| Dec 31, 2012 |
1,588.25% |
| Sep 30, 2012 |
130.16% |
| Jun 30, 2012 |
509.89% |
| Mar 31, 2012 |
92.46% |
